Member access

4-Traders Homepage  >  Shares  >  Euronext Paris  >  BioAlliance Pharma SA    C4X   

 SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials (€)
Sales 2015 6,97 M
EBIT 2015 -16,3 M
Net income 2015 -17,4 M
Debt 2015 11,2 M
Yield 2015 -
Sales 2016 18,4 M
EBIT 2016 -11,1 M
Net income 2016 -12,4 M
Debt 2016 12,6 M
Yield 2016 -
PER 2015 -
PER 2016
EV / Sales 2015 33,1x
EV / Sales 2016 12,6x
Capitalization 220 M
More Financials
Company
Onxeo SA engages in the development of drugs for the treatment of cancer.The firm produces and develops ophan oncology products under the brand names Livatag, Validive, Beleodaq, and AMEP.It also offers specialty products under the brand names Loramyc/Oravig, Sitavig, and Fluriad.The company was... 
Sector
Pharmaceuticals
Calendar
09/23Earnings Release
More about the company
Surperformance© ratings of BioAlliance Pharma SA
Trading Rating : Investor Rating :
More Ratings
Latest news on BIOALLIANCE PHARMA SA
05:59p ONXEO : Announces Preclinical & Clinical Data from Three Studies Supporting the ..
05/28 ONXEO : Announces Preclinical & Clinical Data from Three Studies Supporting the ..
05/27 ONXEO : Announces Final Data from Completed Phase II Trial of Validive® for the ..
05/27 ONXEO : Announces Final Data from Completed Phase II Trial of Validive® for the ..
05/21 ONXEO : Disclosure of Total Number of Voting Rights and Number of Shares in the ..
05/20 ONXEO : Combined General Meeting of Shareholders – Forløb af Onxeos ordinæ..
05/13 ONXEO : Publication of a Letter to Shareholders – May 2015
05/07 ONXEO : Oral Presentation of Phase II Trial Results of Validive® at the MASCC/IS..
More news
Sector news : Pharmaceuticals - NEC
05:32pDJNew Cancer Immunotherapy Drugs Show Promise -- Update
04:24p ALEXION PHARMACEUTICALS : and Synageva Announce Early Termination of Hart-Scott-..
02:46p OPKO HEALTH : Announces Submission of Rayaldee™ New Drug Application to U...
More sector news : Pharmaceuticals - NEC
Comments 
Advertisement
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions